$TNON

Tenon Medical (NASDAQ:TNON) launched its SImmetry+ SI Joint Fusion System, generating $1.2M in revenue during its alpha phase. The company plans to expand inventory to meet demand and expects more product launches. The system received positive physician feedback and aims to address a broader range of patient anatomies. Tenon believes this platform will drive growth and solidify its market position.

Tenon Medical, Inc. (TNON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Tenon Medical Announces Warrant Inducement for Aggregate Gross Proceeds of Approximately $2,872,338 LOS GATOS, CA / ACCESS Newswire / September 11, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) (“Tenon” or the “Company”), a medical device company dedicated to transforming

Tenon Medical (TNON) closed a warrant inducement offering, raising $2,872,338.58. The company issued new warrants for 858,269 shares at $5.02 per share, exercisable immediately. The funds will be used for general corporate purposes, excluding fees and expenses.

Tenon Medical (TNON) announced a warrant inducement deal with an institutional investor, exercising existing warrants for $2.87M in gross proceeds. The company will issue new warrants for 858,269 shares at $5.02 per share, exercisable immediately. The transaction is expected to close on September 14, 2026, subject to customary conditions.

HRT FINANCIAL LP sold 125,925 shares of Tenon Medical, Inc. (TNON) at an average of $4.28 ($2.61–$5.56, $0.54M total) across 3 trades over 2026-09-09 to 2026-09-10.

HRT FINANCIAL LP purchased 108,140 shares of Tenon Medical, Inc. (TNON) at an average of $3.54 ($2.92–$4.92, $0.38M total) across 5 trades over 2026-09-08 to 2026-09-10.

Tenon Medical Inc. (NASDAQ: TNON) shares surged 53.64% after repaying $5.16M in convertible notes, reducing debt risk. The company reported Q2 2026 revenue of $1.3M, up 127% YoY, with a 64% gross margin. Despite strong growth, TNON faces financial challenges, including a $4.05M net loss and negative equity. Traders are monitoring the stock due to its volatility and recent catalysts, such as FDA clearance and increased surgical volume.

Tenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.

Tenon Medical (NASDAQ:TNON) shares rose 23.77% in after-hours trading after repaying $5.16M in convertible notes early, reducing dilution risk. The company develops devices for sacroiliac joint disorders. Its market cap is $1.63M, with a 52-week range of $2.40-$50.40. The stock closed at $2.44, down 27.38% on Wednesday.

Tenon Medical (NASDAQ:TNON) repaid $5.16M in convertible notes early, strengthening its balance sheet and avoiding potential share dilution. The company aims to maintain financial flexibility for growth and commercialization of its medical devices, according to its CEO.